Advances in manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step batch manufacturing processes to faster, and relatively more efficient continuous manufacturing
The global continuous manufacturing market size is estimated to be worth USD 2,080 million in 2023 and anticipated to grow at a CAGR of 6.4% during the forecast period.
For decades, pharmaceutical companies have been using batch processing method for drug manufacturing, wherein a specific quantity of a drug is produced through multiple sequential steps. However, batch processing / batch manufacturing of a drug substance or drug products can be slow and inefficient. As a result, drug developers have begun to adopt continuous manufacturing systems to streamline drug production process. Continuous manufacturing involves the production of pharmaceutical drug substance / drug products in a single run, while operating 24×7. In this process, the drug is developed from its base ingredients / raw materials and processed to the final product in one facility, without any hold time. This technique offers several advantages over traditional batch processing, which includes reduction in facility footprint (by 70%), reduction in operational and running costs (by 40-50%) and easy scale up.
Further, the outbreak of COVID-19 pandemic fueled the growth of the global market of continuous manufacturing; this can be attributed to the fact that that traditional batch processing relies on complex supply chain to manufacture raw materials for API manufacturing. On the contrary, continuous manufacturing can easily accommodate scale-up and post-approval changes in drug production which is advantageous in case of drug shortages. Biden administration has supported increased funding of pharmaceutical continuous manufacturing technologies to overcome challenges associated with pharmaceutical supply chain. Such developments will support the continuous manufacturing market growth.
Presently, close to 60 manufacturers have adopted continuous manufacturing for single or multiple unit operations. Various types of biologics, including antibodies, enzymes, proteins / peptides, vaccines and viral vectors can be synthesized utilizing continuous manufacturing technique. It is worth noting that close to 75% of the continuous biologic manufacturers offer contract manufacturing services for continuous manufacturing of the above mentioned biologics.
Majority of these manufacturers are headquartered in North America (~40%) followed by Europe and Asia Pacific. Most of the continuous biologic manufacturers possess the expertise for continuous cell culturing (86%); this can be attributed to the fact that upstream bioprocessing is comparatively more established, owing to the extensive usage of perfusion technologies by the biologic manufacturers from past two decades. It is worth noting that presently antibodies are the most common biologic for which continuous bioprocessing is currently being adopted.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Continuous Manufacturing Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To get sample report visit@
https://www.rootsanalysis.com/reports/continuous-manufacturing/request-sample.html
